{"id":"cldn18-2","name":"Claudin 18.2","symbol":"CLDN18","route":"/targets/cldn18-2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2039","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066405","uniprot":"https://www.uniprot.org/uniprotkb/P56856/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P56856","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712859","open-targets":"https://platform.opentargets.org/target/ENSG00000066405","civic":"https://civicdb.org/genes/51208/summary","oncokb":"https://www.oncokb.org/gene/CLDN18","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLDN18","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CLDN18","depmap":"https://depmap.org/portal/gene/CLDN18?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000066405-CLDN18","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/51208","omim":"https://www.omim.org/entry/609210"}],"products":[{"id":"asp2138","name":"ASP2138","status":"phase-3","modality":"bispecific antibody","route":"/drugs/asp2138/"},{"id":"azd4360","name":"AZD4360","status":"phase-2","modality":"ADC","route":"/drugs/azd4360/"},{"id":"azd5863","name":"AZD5863","status":"phase-2","modality":"bispecific antibody","route":"/drugs/azd5863/"},{"id":"bdc-4182","name":"BDC-4182","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/bdc-4182/"},{"id":"ibi343","name":"IBI343","status":"phase-3","modality":"antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record","route":"/drugs/ibi343/"},{"id":"lb4330","name":"LB4330","status":"phase-2","modality":"fusion protein","route":"/drugs/lb4330/"},{"id":"lcb02a","name":"LCB02A","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/lcb02a/"},{"id":"lm-302","name":"LM-302","status":"phase-3","modality":"ADC","route":"/drugs/lm-302/"},{"id":"m108","name":"M108","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/m108/"},{"id":"rc118-adc","name":"RC118-ADC","status":"phase-2","modality":"ADC","route":"/drugs/rc118-adc/"},{"id":"satricabtagene-autoleucel","name":"Satricabtagene autoleucel","status":"approved","modality":"CAR-T (Claudin 18.2)","route":"/drugs/satricabtagene-autoleucel/"},{"id":"cmg901","name":"Sonesitatug vedotin","status":"phase-3","modality":"ADC","route":"/drugs/cmg901/"},{"id":"spevatamig","name":"Spevatamig","status":"phase-2","modality":"bispecific antibody","route":"/drugs/spevatamig/"},{"id":"tac01-cldn18-2","name":"TAC01-CLDN18.2","status":"phase-2","modality":"TCR-T cell therapy","route":"/drugs/tac01-cldn18-2/"},{"id":"xnw27011","name":"XNW27011","status":"phase-2","modality":"ADC","route":"/drugs/xnw27011/"},{"id":"zolbetuximab","name":"Zolbetuximab","status":"approved","modality":"Monoclonal antibody (anti-Claudin 18.2)","route":"/drugs/zolbetuximab/"}],"trials":[{"id":"clarity-gastric01","name":"CLARITY-Gastric 01","nct":"NCT06346392","phase":"3","status":"positive"},{"id":"spotlight-glow","name":"SPOTLIGHT & GLOW","nct":"NCT03504397","phase":"3","status":"positive"},{"id":"g-hope-002","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","nct":"NCT07066098","phase":"3","status":"recruiting"},{"id":"nct07673887","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","nct":"NCT07673887","phase":"3","status":"recruiting"},{"id":"nct06901531","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","nct":"NCT06901531","phase":"3","status":"recruiting"},{"id":"nct07385703","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","nct":"NCT07385703","phase":"3","status":"recruiting"},{"id":"nct06177041","name":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","nct":"NCT06177041","phase":"3","status":"recruiting"},{"id":"nct07431281","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","nct":"NCT07431281","phase":"3","status":"recruiting"},{"id":"nct05934331","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","nct":"NCT05934331","phase":"2","status":"recruiting"},{"id":"nct07069712","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","nct":"NCT07069712","phase":"2","status":"recruiting"},{"id":"nct03505320","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","nct":"NCT03505320","phase":"2","status":"active"},{"id":"nct03816163","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","nct":"NCT03816163","phase":"2","status":"active"},{"id":"nct06219941","name":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","nct":"NCT06219941","phase":"2","status":"recruiting"},{"id":"nct07108504","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","nct":"NCT07108504","phase":"2","status":"planned"},{"id":"nct07415525","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","nct":"NCT07415525","phase":"2","status":"planned"},{"id":"nct06770439","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","nct":"NCT06770439","phase":"2","status":"recruiting"},{"id":"nct07483554","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","nct":"NCT07483554","phase":"2","status":"recruiting"},{"id":"nct04581473","name":"CT041-ST-01","nct":"NCT04581473","phase":"1/2","status":"positive"},{"id":"nct06921837","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","nct":"NCT06921837","phase":"1/2","status":"recruiting"},{"id":"nct05205850","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","nct":"NCT05205850","phase":"1/2","status":"recruiting"},{"id":"nct06038396","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","nct":"NCT06038396","phase":"1/2","status":"recruiting"},{"id":"nct07460375","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","nct":"NCT07460375","phase":"1/2","status":"recruiting"},{"id":"nct06468358","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","nct":"NCT06468358","phase":"1/2","status":"recruiting"},{"id":"nct07692750","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","nct":"NCT07692750","phase":"1/2","status":"recruiting"},{"id":"nct05482893","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","nct":"NCT05482893","phase":"1/2","status":"recruiting"},{"id":"nct06921928","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","nct":"NCT06921928","phase":"1/2","status":"active"},{"id":"nct06005493","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","nct":"NCT06005493","phase":"1/2","status":"recruiting"},{"id":"nct05862324","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","nct":"NCT05862324","phase":"1/2","status":"active"},{"id":"nct06792435","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","nct":"NCT06792435","phase":"1/2","status":"active"}],"pathways":["gastric-cancer-signalling"],"companies":["astellas","astrazeneca","bolt-biotherapeutics","carsgen","hutchmed","innovent","keymed","ligachem-biosciences","phanes-therapeutics","remegen","sino-biopharm","triumvira-immunologics","xilio-therapeutics"],"keyPapers":["paper-ct041-st-01-lancet-2025","paper-spotlight-lancet-2023"],"hotspots":[],"openQuestions":[{"id":"cldn18-2-adc-vs-antibody","question":"Should CLDN18.2 be attacked with an antibody plus chemotherapy, an ADC, or CAR-T, and at what expression threshold?","stage":"clinical","actor":"industry","source":{"label":"CLARITY-Gastric 01 (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT06346392"}}],"assays":[{"id":"cldn18-ventana","name":"VENTANA CLDN18 (43-14A) RxDx Assay","cutoff":"At least 75% of tumour cells with moderate-to-strong membranous staining (zolbetuximab, gastric and gastro-oesophageal junction adenocarcinoma)"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}